Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2023-03-15 Director's Dealing
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-03-15 English
Director's Dealing 2023
Director's Dealing
2023-03-15 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 14, 2023. It includes a press release about a bioproduction platform and explicitly states it is furnished pursuant to Item 7.01 Regulation FD Disclosure. The document does not contain financial statements or detailed financial data but rather an announcement of a press release. The length is 4259 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes information without substantive financial data or full report content should be classified as a Regulatory Filing (RNS).
2023-03-14 English
Board/Management Information 2023
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer, Kevin M. Coveney, including his background, employment agreement, and the resignation of the previous CFO. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length and detail support a high confidence in this classification.
2023-02-28 English
Board/Management Information 2023
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 23, 2023, for Enveric Biosciences, Inc. It announces the appointment of a new Vice President, Clinical Operations, and an inducement grant under Nasdaq Listing Rule 5635(c)(4). The document includes a press release as an exhibit and does not contain detailed financial statements or comprehensive financial data. The content focuses on management changes rather than financial results or other report types. Given the nature of the announcement about a senior management appointment, this fits the category of Board/Management Information (MANG). The document length is 4310 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2023-02-23 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.